CADL
Price
$9.22Alerts
Change
-$0.13 (-1.39%)
Updated
Nov 11 closing price
Capitalization
669.54M
Earnings call today
Intraday BUY SELL Signals
CRVO
Price
$1.77Alerts
Change
+$0.40 (+29.20%)
Updated
Nov 11 closing price
Capitalization
21.47M
144 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CADL vs CRVO

CADL vs CRVO Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
CADL vs. CRVO commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CADL is a Hold and CRVO is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for CADL with price predictions
Nov 11, 2026

CADL's RSI Oscillator recovers from oversold territory

The RSI Oscillator for CADL moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on CADL as a result. In 91 of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.

The Moving Average Convergence Divergence (MACD) for CADL just turned positive on October 28, 2026. Looking at past instances where CADL's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.

Following a +18.04% 3-day Advance, the price is estimated to grow further. Considering data from situations where CADL advanced for three days, in 213 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CADL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.

CADL broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CADL entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CADL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.308) is normal, around the industry mean (3.498). P/E Ratio (-5.952) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CADL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for CRVO with price predictions
Nov 11, 2026

CRVO in downward trend: price dove below 50-day moving average on October 12, 2026

CRVO moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 33 of 36 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CRVO as a result. In 88 of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for CRVO turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 42 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

The 10-day moving average for CRVO crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CRVO entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRVO's RSI Indicator exited the oversold zone, 30 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

CRVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.935) is normal, around the industry mean (3.498). P/E Ratio (-0.442) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CRVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
CRVO: Fundamental Ratings
CRVO
OUTLOOK RATING
1..100
92
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
99
PRICE GROWTH RATING
1..100
95
P/E GROWTH RATING
1..100
10
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CADLCRVO
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
N/A
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (CADL: $9.35 vs. CRVO: $1.77)
Brand notoriety: CADL and CRVO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CADL: 48% vs. CRVO: 2045%
Market capitalization -- CADL: $669.54M vs. CRVO: $21.47M
CADL [@Biotechnology] is valued at $669.54M. CRVO’s [@Biotechnology] market capitalization is $21.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CADL’s FA Score shows that 1 FA rating(s) are green while CRVO’s FA Score has 1 green FA rating(s).

  • CADL’s FA Score: 1 green, 4 red.
  • CRVO’s FA Score: 1 green, 4 red.
According to our system of comparison, CADL is a better buy in the long-term than CRVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CADL’s TA Score shows that 4 TA indicator(s) are bullish while CRVO’s TA Score has 3 bullish TA indicator(s).

  • CADL’s TA Score: 4 bullish, 4 bearish.
  • CRVO’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, CADL is a better buy in the short-term than CRVO.

Price Growth

CADL (@Biotechnology) experienced а +6.01% price change this week, while CRVO (@Biotechnology) price change was +13.46% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

CADL is expected to report earnings on Nov 12, 2026.

CRVO is expected to report earnings on Apr 05, 2027.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

CADL and

Correlation & Price change

A.I.dvisor indicates that over the last year, CADL has been loosely correlated with EDIT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CADL jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CADL
1D Price
Change %
CADL100%
-1.39%
EDIT - CADL
50%
Loosely correlated
-4.99%
FDMT - CADL
48%
Loosely correlated
+4.25%
NTLA - CADL
48%
Loosely correlated
+2.15%
CRSP - CADL
47%
Loosely correlated
+1.33%
SANA - CADL
47%
Loosely correlated
-5.76%
More

CRVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRVO has been loosely correlated with SLBT. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if CRVO jumps, then SLBT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRVO
1D Price
Change %
CRVO100%
+29.20%
SLBT - CRVO
35%
Loosely correlated
-19.64%
NMRA - CRVO
34%
Loosely correlated
+1.37%
CADL - CRVO
30%
Poorly correlated
-1.39%
ONCY - CRVO
29%
Poorly correlated
+7.81%
VRCA - CRVO
29%
Poorly correlated
+11.08%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AUID0.180.01
+7.46%
authID
TREE36.841.49
+4.21%
LendingTree
CLOV4.970.04
+0.81%
Clover Health Investments Corp
MAA118.19-0.67
-0.56%
Mid-America Apartment Communities
SERA1.94-0.05
-2.51%
Sera Prognostics